11.1 Triple-Negative Breast Cancer: Treatment Considerations
Key Takeaways
Triple-negative breast cancer is ER-negative, PR-negative, and HER2-negative and makes up roughly 10% to 15% of breast cancers, with higher rates in young women, Black women, and BRCA1 carriers.
For TNBC that is cT1c N1–2 or cT2–4 N0–2, KEYNOTE-522 neoadjuvant pembrolizumab with carboplatin-paclitaxel followed by an anthracycline regimen, then adjuvant pembrolizumab, is the standard pathway.
Residual TNBC after neoadjuvant therapy is treated with continued pembrolizumab and may add capecitabine (CREATE-X) or, for germline BRCA carriers, 1 year of olaparib (OlympiA).
First-line metastatic TNBC with PD-L1 combined positive score of 10 or higher is treated with pembrolizumab plus chemotherapy (KEYNOTE-355); sacituzumab govitecan is a standard later-line option.
TNBC recurrences peak within 2 to 3 years of diagnosis and often involve viscera and brain, while recurrence after 5 years is uncommon.
Defining Triple-Negative Disease
Triple-negative breast cancer (TNBC) lacks estrogen receptor (ER below 1%), progesterone receptor (PR below 1%), and HER2 overexpression or amplification (IHC 0, 1+, or 2+ with negative ISH). Tumors with ER-low expression (1% to 10%) often behave like TNBC and are frequently treated on TNBC pathways.
TNBC accounts for roughly 10% to 15% of breast cancers. It is more common in women under 40, non-Hispanic Black women, and BRCA1 carriers. Tumors are usually high grade with a high Ki-67. Gene expression studies (Lehmann subtypes) show TNBC is not one disease: basal-like, mesenchymal, immunomodulatory, and luminal androgen receptor groups respond differently to therapy. Because TNBC lacks endocrine and HER2 targets, chemotherapy, immunotherapy, PARP inhibitors, and antibody-drug conjugates are the main tools.
Early-Stage Pathway by Tumor Size and Nodes
| Clinical presentation | Usual approach |
|---|---|
| T1a N0 (5 mm or smaller) | Surgery; systemic chemotherapy usually not needed |
| T1b N0 (over 5 mm to 10 mm) | Surgery; adjuvant chemotherapy considered |
| T1c N0 | Chemotherapy recommended; neoadjuvant therapy may be considered |
| cT1c N1–2 or cT2–4 N0–2 | Neoadjuvant chemoimmunotherapy (KEYNOTE-522), then surgery and adjuvant therapy |
The KEYNOTE-522 Regimen
- Neoadjuvant phase 1 (12 weeks): pembrolizumab 200 mg every 3 weeks with weekly paclitaxel and carboplatin (weekly or every 3 weeks).
- Neoadjuvant phase 2: four cycles of doxorubicin or epirubicin with cyclophosphamide, plus pembrolizumab.
- Surgery, then radiation as indicated.
- Adjuvant pembrolizumab for 9 more cycles, completing about 1 year of immunotherapy.
Pembrolizumab raised pathologic complete response from 51.2% to 64.8%, improved event-free survival, and in 2024 showed an overall survival benefit (5-year overall survival 86.6% versus 81.7%). The benefit was seen regardless of PD-L1 status, so PD-L1 testing is not required in early disease.
After Surgery: Response-Adapted Therapy
- Pathologic complete response (ypT0/is ypN0): complete adjuvant pembrolizumab; prognosis is excellent.
- Residual invasive disease: continue pembrolizumab. Adding capecitabine (CREATE-X showed improved disease-free and overall survival in the TNBC subgroup) is an option.
- Germline BRCA1/2 carriers with high-risk disease: 1 year of olaparib (OlympiA) reduced invasive recurrence and death. This is why every patient with TNBC should be referred for germline genetic testing early, ideally before surgery, because results can also change surgical choices.
Radiation follows standard criteria. Breast conservation is as safe for TNBC as for other subtypes when margins are negative.
Metastatic TNBC
- Test PD-L1 using the 22C3 assay. For a combined positive score (CPS) of 10 or higher, first-line pembrolizumab plus chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine-carboplatin) improved overall survival in KEYNOTE-355.
- Test germline BRCA: PARP inhibitors (olaparib or talazoparib) are options for carriers; platinum chemotherapy is also active.
- Later lines: sacituzumab govitecan after at least two prior therapies (at least one for metastatic disease); trastuzumab deruxtecan if the tumor is HER2-low; single-agent chemotherapy such as eribulin, capecitabine, or vinorelbine.
- Brain metastases are common; new headaches, neurologic deficits, or seizures need brain MRI.
Recurrence Pattern
TNBC recurrences cluster early, peaking within 2 to 3 years, and favor lung, liver, and brain. Risk falls steeply after 5 years, which contrasts with ER-positive disease, where late recurrences continue for decades. Survivorship still follows standard surveillance without routine scans.
Nursing Priorities
- Genetic referral for every patient with TNBC (an NCCN testing criterion at any age).
- Immunotherapy safety: baseline thyroid, adrenal, liver, and kidney tests; wallet card; teach that new diarrhea, cough, rash, extreme fatigue, or headache may signal an immune-related adverse event, including after treatment ends. Adrenal insufficiency and hypothyroidism from pembrolizumab may be permanent.
- Chemotherapy toxicity: carboplatin-paclitaxel plus an anthracycline brings neutropenia, anemia, thrombocytopenia, neuropathy, and nausea.
- Fertility and psychosocial support: many patients are young; offer fertility preservation before chemotherapy and address fear related to the aggressive reputation of TNBC.
- Adherence to oral capecitabine or olaparib: teach hand-foot syndrome grading, diarrhea management, and anemia monitoring.
Special Situations in TNBC
- ER-low disease (1% to 10%): behaves much like TNBC; many teams use TNBC pathways, including KEYNOTE-522, while still discussing endocrine therapy.
- Luminal androgen receptor (LAR) subtype: some TNBCs express androgen receptor; they respond less to chemotherapy, and androgen-directed therapy is investigational.
- Immune-related adverse events before surgery: adrenal insufficiency or hypothyroidism from pembrolizumab can surface around the time of surgery. Nurses check thyroid function and ask about fatigue, dizziness, nausea, and low blood pressure; patients with adrenal insufficiency need stress-dose steroids for surgery.
- Older or frail patients: regimens are adapted after geriatric assessment; immunotherapy benefit must be weighed against toxicity.
- Pregnancy: anthracycline-based chemotherapy can be given after the first trimester, but pembrolizumab is avoided during pregnancy.
Case Walk-Through
A 38-year-old with a 3.5-cm triple-negative cancer and a biopsy-proven axillary node (cT2 N1):
- Before treatment: clip the node, refer for genetic testing and fertility preservation, obtain baseline thyroid, cortisol, liver, and kidney tests, and place a port.
- Neoadjuvant phase: weekly paclitaxel and carboplatin with pembrolizumab; monitor counts, neuropathy, and immune symptoms; then doxorubicin-cyclophosphamide with pembrolizumab, watching for febrile neutropenia and nausea.
- Surgery: lumpectomy or mastectomy with targeted axillary dissection; plan radiation.
- Adjuvant phase: complete pembrolizumab; if residual disease, discuss capecitabine; if she carries a germline BRCA variant, discuss olaparib.
- Survivorship: surveillance without routine scans, fertility and contraception counseling, management of any permanent endocrine side effects, and psychological support for fear of recurrence.
A 42-year-old with cT2 N1 triple-negative breast cancer completes the KEYNOTE-522 regimen and has 1.2 cm of residual invasive disease at surgery. Germline testing shows a BRCA2 pathogenic variant. Which adjuvant plan best reflects current evidence?
Stop all systemic therapy because the tumor responded partially.
Switch to trastuzumab-based therapy for 1 year.
Start tamoxifen for 5 years.
Continue adjuvant pembrolizumab, and consider 1 year of olaparib because she is a germline BRCA carrier with residual disease.
A patient with newly diagnosed metastatic triple-negative breast cancer asks why her oncologist ordered a PD-L1 test. What is the best explanation?
A combined positive score of 10 or higher identifies patients who benefit from adding pembrolizumab to first-line chemotherapy.
PD-L1 status determines whether she is eligible for trastuzumab.
PD-L1 testing is required before any chemotherapy can be given.
PD-L1 identifies inherited BRCA variants.
A survivor treated for stage II triple-negative breast cancer 7 years ago asks whether her risk of recurrence is the same as when she finished treatment. Which statement is most accurate?
TNBC recurrences usually occur 10 to 20 years after diagnosis.
Her risk is unchanged for life, so she needs annual PET scans.
TNBC recurrences peak in the first 2 to 3 years, and risk falls substantially after 5 years, although standard surveillance continues.
She should start tamoxifen now to prevent late recurrence.
Sections you finish are checked off in the contents.